ストックスクリーナーアプリを入手
4.12
1.44%
-0.06
Sab Biotherapeutics Inc (SABS) 最新ニュース
SAB BIO to Participate in Upcoming Investor Conferences - Investing News Network
Aug Momentum: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantTrade Entry Summary & Risk Controlled Daily Plans - baoquankhu1.vn
SAB Biotherapeutics, Inc. Management to Participate in February Investor Conferences - Quiver Quantitative
Biotech firm SAB Biotherapeutics joins fireside chats at 2 Feb. investor events - Stock Titan
Published on: 2026-01-31 17:26:58 - baoquankhu1.vn
Can SAB Biotherapeutics Inc. weather a recessionJuly 2025 Price Swings & Long-Term Safe Return Strategies - mfd.ru
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in SAB Biothe - GuruFocus
SAB Biotherapeutics Shares Jump 33% After Securing $175M in Oversubscribed Private Placement - MSN
Aug Patterns: Whats HTGCs historical return2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
Insider Sell: Is SAB Biotherapeutics Inc a cyclical or defensive stockQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Investment Review: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantQuarterly Risk Review & High Conviction Investment Ideas - baoquankhu1.vn
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Mood: Is SAB Biotherapeutics Inc Equity Warrant stock undervalued right nowJuly 2025 Earnings & Low Drawdown Trading Techniques - baoquankhu1.vn
SAB Biotherapeutics phase 1 trial of SAB-142 met primary endpoint - MSN
HB Wealth Management LLC Buys New Stake in SAB Biotherapeutics, Inc. $SABS - MarketBeat
Portfolio Update: Will SAB Biotherapeutics Inc. Equity Warrant stock continue upward momentumTrend Reversal & Growth Focused Entry Point Reports - Bộ Nội Vụ
Published on: 2026-01-13 04:34:13 - Улправда
SAB Biotherapeutics, Inc. Updates on SAB-142 Development - TradingView
SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades SAB Biotherapeutics (NASDAQ:SABS) to "Strong-Buy" - MarketBeat
Cash per share of SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap – NASDAQ:SABSW - TradingView — Track All Markets
Will SAB Biotherapeutics Inc. stock continue dividend increasesJuly 2025 Levels & Daily Profit Focused Stock Screening - Улправда
Why SAB Biotherapeutics Inc. stock remains on buy listsJuly 2025 Movers & Verified Momentum Stock Watchlist - Улправда
Will SAB Biotherapeutics Inc. stock see insider buying2025 Earnings Impact & Risk Adjusted Buy and Sell Alerts - Улправда
Is SAB Biotherapeutics Inc. stock a buy on dipsMarket Growth Summary & High Accuracy Swing Entry Alerts - ulpravda.ru
Why SAB Biotherapeutics Inc. stock attracts global investorsQuarterly Market Review & Detailed Earnings Play Strategies - Улправда
Why SAB Biotherapeutics Inc. Equity Warrant stock is recommended by analystsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Los Angeles Daily NewsSAB Biotherapeutics, Inc.Common Stock (Nasdaq:SABS) Stock Quote - FinancialContent
Published on: 2026-01-07 16:05:26 - bollywoodhelpline.com
UBS Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation - Nasdaq
SAB Biotherapeutics, Inc.Warrant (NQ: SABSW - FinancialContent
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director - GlobeNewswire
Two veteran drug leaders join the board behind a new Type 1 diabetes therapy - Stock Titan
SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential - Investing.com Canada
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Increase in Short Interest - MarketBeat
SAB Biotherapeutics Launches New $75 Million ATM Program - The Globe and Mail
SAB Biotherapeutics Files $300 Million Mixed Shelf - MarketScreener
Sab Biotherapeutics files for offering of up to $300 mln - marketscreener.com
SAB Biotherapeutics enters sales agreement with UBS SecuritiesSEC filing - MarketScreener
SAB Biotherapeutics Enters Sales Agreement With UBS SecuritiesSEC Filing - TradingView — Track All Markets
SAB Biotherapeutics Establishes New At-the-Market Offering Program - TradingView — Track All Markets
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is SAB Biotherapeutics Inc. stock a good choice for value investorsBlue Chip Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
SABS SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SAB Biotherapeutics Earnings Notes - Trefis
Will SAB Biotherapeutics Inc. Equity Warrant stock continue dividend increases2025 Pullback Review & AI Forecasted Entry and Exit Points - Улправда
What margin trends mean for SAB Biotherapeutics Inc. stockJuly 2025 Setups & Verified Entry Point Detection - Улправда
Guggenheim Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on SAB Biotherapeutics With Buy Rating, $15 Price Target - marketscreener.com
Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential - Investing.com Canada
Will SAB Biotherapeutics Inc. Equity Warrant stock deliver consistent dividends2025 Risk Factors & Real-Time Chart Breakout Alerts - DonanımHaber
Will SAB Biotherapeutics Inc. Equity Warrant stock outperform international peers2025 Technical Overview & Community Verified Watchlist Alerts - Улправда
Why SAB Biotherapeutics Inc. stock is favored by top institutionsProfit Target & Low Risk High Reward Trade Ideas - Улправда
SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at Chardan Capital - Defense World
Will SAB Biotherapeutics Inc. Equity Warrant stock continue upward momentum2025 Support & Resistance & Low Volatility Stock Suggestions - Улправда
SAB Biotherapeutics (SABS) director Jay S. Skyler granted 150,000 stock options - Stock Titan
Chardan Capital Maintains SAB Biotherapeutics (SABS) Buy Recommendation - Nasdaq
SAB Biotherapeutics (SABS) director awarded 150,000 stock options for 2025 - Stock Titan
SAB Biotherapeutics grants director option for 150,000 shares at $3.99 | SABS SEC FilingForm 4 - Stock Titan
SAB Biotherapeutics (SABS) director gets 150,000 options at $3.99 - Stock Titan
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):